Lifecore biomedical announces intent to explore strategic alternatives

Chaska, minn., march 16, 2023 (globe newswire) -- lifecore biomedical, inc. (“lifecore” or the “company”), a fully integrated contract development and manufacturing organization (“cdmo”), today announced that the board of directors of the company (the “board”) intends to initiate a process to evaluate the company's potential strategic alternatives to maximize value for stockholders. as part of the process, the board intends to consider a full range of strategic alternatives, which could include a sale of the company, potential debt or equity financing transactions, or other possible strategic transactions.
LFCR Ratings Summary
LFCR Quant Ranking